<DOC>
	<DOCNO>NCT00199862</DOCNO>
	<brief_summary>The purpose study determine whether drug , 124I-huA33 , safely detect colorectal cancer .</brief_summary>
	<brief_title>Safety Study Radio-labeled huA33 Antibody Colorectal Cancer</brief_title>
	<detailed_description>This open-label , pilot study single 4mCi-10mCi/10mg IV dose 124I-huA33 patient colorectal cancer . Patients study 124I-huA33 positron-emission tomography ( PET ) , subset patient schedule surgery , base clinical indication , ex vivo quantitation tumor uptake also perform . Patients receive single intravenous intraarterial infusion 4 mCi-10mCi /10mg 124I-huA33 5-30ml 5 % human serum albumin ( HSA ) , 5-10 minute . Patient either receive 124I-huA33 intravenously ( IV ) intraarterially ( IA ) determine advantage IV v IA route . Following injection 124I-huA33 , study day 2 , 3 , and/ 4 , patient option receive 2g/1kg Immune Globulin ( IVIG ) . Blood sample obtain pharmacokinetic analysis 5 , 15 , 60 , 120 minute completion IV IA infusion , day 2 , 3 , and/ 4 , PET scan day surgery last imaging day ( day 8 + 3 ) . Patients schedule surgery undergo PET scan abdomen pelvis 1-6 hour prior surgery . In patient undergo surgery , surgery ( biopsy ) schedule occur day 8 ( ± 3 day ) day administration 124I-huA33 . Biopsy sit may include tumor , tumor bed , regional node , portal , suprapancreatic , celiac node retroperitoneum . Tumor normal tissue obtain surgery ( biopsy ) , serum measure estimation percent-injected dose per gram tumor , normal liver , serum . Tissue sample obtain autoradiography immunohistochemistry additional assessment tumor target . Blood sample determine immunogenicity take baseline 4 week . Toxicity assessment make throughout study period .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Primary metastatic colorectal carcinoma , histologically confirm Memorial SloanKettering Cancer Center ( MSKCC ) . Patients must candidate clinically indicate surgery/biopsy primary/metastatic colorectal cancer Expected survival least 3 month . Karnofsky performance status ≥ 70 ( ECOG 0 1 ) . The following laboratory result within last 2 week prior study day 1 : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 75 x 109/L Serum bilirubin ≤ 2.5 mg/dL Serum creatinine ≤ 2.0 mg/dL White Blood Count ( WBC ) ≥ 3,000/mm3 Age ≥ 18 year . Children age include colon cancer extremely rare child . Women childbearing potential confirm negative pregnancy test day administration study agent . Before trialspecific procedure treatment perform , patient patient 's legally authorize guardian representative must give witnessed write informed consent participation tria Clinically significant cardiac disease ( New York Heart Association Class III/IV ) . Active CNS tumor involvement . Previous treatment A33 fragment and/or positive test huA33 HAHA . Lack availability immunological clinical followup assessment . Participation clinical trial involve another investigational agent within 4 week prior enrollment . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>huA33</keyword>
	<keyword>antibody</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>Iodine 124</keyword>
	<keyword>124I</keyword>
	<keyword>03-124</keyword>
</DOC>